What is it?
Identity
1Pyritinol is a synthetic disulfide compound derived from pyridoxine chemistry. It is not vitamin B6 and does not share the minimal-risk nutrition profile of ordinary B6 intake.
Evidence boundary
2Older trials in clinical populations do not establish improved cognition, memory, or focus in healthy adults.
Names, aliases and forms
Potential effects and evidence map
Evidence comes mainly from older clinical populations and is not transferable to healthy-user cognition. Serious hepatitis reports materially outweigh the weak nootropic evidence.
Timing & effect horizon
No reliable acute onset, effect duration, or routine nootropic cycle is established.
Safety, side effects and risk profile
Published reports describe clinically serious hepatitis associated with pyritinol.
The evidence base is old, population-specific, and inadequate for healthy-user nootropic use.
Published case series describe serious and prolonged hepatitis associated with pyritinol. Although the absolute frequency is not established, this material hazard outweighs the uncertain healthy-user benefit.
Practical buying and quality notes
- Do not mistake pyritinol for a nutritional B6 supplement. Verify identity and weigh the serious liver signal against the absence of established healthy-user benefit.5
FAQ
Pyritinol versus vitamin B6
1No. Pyritinol is a synthetic pyridoxine-derived disulfide compound, not an essential B6 vitamer. It does not share the nutritional evidence or minimal-risk profile of ordinary vitamin B6 intake.
References
- PubChem. Compound Summary for CID 14190, Pyritinol.
- Cooper AJ, Magnus RV. A placebo-controlled study of pyritinol (Encephabol) in dementia. Pharmatherapeutica. 1980.
- Fischhof PK, Saletu B, Ruther E, Litschauer G, Moslinger-Gehmayr R, Herrmann WM. Therapeutic efficacy of pyritinol in patients with senile dementia of the Alzheimer type and multi-infarct dementia. Neuropsychobiology. 1992.
- Knezevic S, Mubrin Z, Risberg J, et al. Pyritinol clinical use of SDAT patients: evaluation by psychiatric and neurological examination, psychometric testing and rCBF measurements. International Clinical Psychopharmacology. 1989.
- Maria V, Albuquerque A, Loureiro A, et al. Severe cholestatic hepatitis induced by pyritinol. BMJ. 2004.